Medicinova, Inc. (MNOV) Stock Price

MNOVStock

$1.57+16.58%52W

Market Cap$77.28M

P/E—

PEG Ratio—

Div yield—

Beta0.65

MNOV Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-13.79%

Price vs S&P 500 (4W)11.99%

VGM Score49.24

Book Value / Share (Quarterly)$0.80

P/TBV (Annual)1.75x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.19

Price vs S&P 500 (YTD)4.83%

Gross Margin (TTM)8.03%

Net Profit Margin (TTM)-1964.15%

EPS (TTM)$-0.24

10-Day Avg Trading Volume0.04M

EPS Excl Extra (TTM)$-0.24

EPS (Annual)$-0.24

ROI (Annual)-28.85%

Gross Margin (Annual)7.58%

Net Profit Margin (5Y Avg)-1094.76%

Cash / Share (Quarterly)$0.56

ROA (Last FY)-26.31%

EBITD / Share (TTM)$-0.26

ROE (5Y Avg)-19.16%

Operating Margin (TTM)-2165.33%

Cash Flow / Share (Annual)$-0.20

P/B Ratio1.66x

P/B Ratio (Quarterly)1.71x

Net Income / Employee (Annual)$-1,999,700

EV / Revenue (TTM)63.92x

Net Interest Coverage (TTM)-10.07x

ROA (TTM)-25.22%

EPS Incl Extra (Annual)$-0.24

Current Ratio (Annual)8.16x

Quick Ratio (Quarterly)8.91x

3-Month Avg Trading Volume0.04M

52-Week Price Return16.58%

Revenue / Employee (TTM)$99,400

Tangible BV / Share (Quarterly)$0.70

P/S Ratio (Annual)159.80x

Asset Turnover (Annual)0.01x

52-Week High$1.96

Operating Margin (5Y Avg)-1184.24%

EPS Excl Extra (Annual)$-0.24

CapEx CAGR (5Y)-40.83%

Tangible BV CAGR (5Y)-11.17%

26-Week Price Return-2.55%

Quick Ratio (Annual)8.11x

13-Week Price Return11.68%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.09x

Enterprise Value$38.13M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-11.82%

Revenue / Employee (Annual)$68,300

Pretax Margin (Annual)-2927.30%

Cash / Share (Annual)$0.63

3-Month Return Std Dev39.48%

Gross Margin (5Y Avg)36.04%

Net Income / Employee (TTM)$-1,953,200

ROE (Last FY)-28.85%

Net Interest Coverage (Annual)342.00x

EPS Basic Excl Extra (Annual)$-0.24

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.24

ROI (TTM)-27.26%

P/S Ratio (TTM)109.72x

Pretax Margin (5Y Avg)-1094.13%

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$0.75

Price vs S&P 500 (52W)-1.73%

Year-to-Date Return16.79%

5-Day Price Return14.18%

EPS Normalized (Annual)$-0.24

ROA (5Y Avg)-17.91%

Net Profit Margin (Annual)-2928.76%

Month-to-Date Return15.04%

Cash Flow / Share (TTM)$-0.19

EBITD / Share (Annual)$-0.27

Operating Margin (Annual)-3242.44%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-19.16%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.24

P/TBV (Quarterly)1.95x

P/B Ratio (Annual)1.55x

Pretax Margin (TTM)-1963.15%

Book Value / Share (Annual)$0.84

Price vs S&P 500 (13W)8.88%

Beta0.65x

P/FCF (Annual)79.83x

Revenue / Share (TTM)$0.01

ROE (TTM)-27.26%

52-Week Low$1.17

vGradeD

mGradeB

vgmGradeC

MNOV Earnings Surprise History

Q2 25-0.07est. -0.12

Q3 25-0.06est. -0.12

Q4 25-0.05est. -0.10

Q1 26-0.05est. -0.07

Q2 26-0.05est. -0.07

MNOV Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.10

4.11

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
MNOVMedicinova, Inc.	D	—	B	$1.57
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Medicinova, Inc.

MediciNova is a biopharmaceutical company that develops small-molecule therapeutics for diseases with unmet medical needs, with particular focus on neurological disorders and fibrotic diseases in the U.S. market. The company's pipeline includes candidates such as MN-001, MN-166, and MN-221, developed through a strategy of acquiring and advancing promising therapeutic assets.